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Abstract.  Despite extensive efforts, little progress has 
been made in identifying the factors that induce he- 
patic fibrosis. Transforming  growth factor-/3 (TGF-/3) 
has been shown to enhance collagen production,  there- 
fore its role in hepatic fibrosis was investigated.  Treat- 
ment of cultured hepatic ceils with TGF-31  increased 
type I procollagen mRNA levels  13-fold due to post- 
transcriptional  gene regulation.  When two animal 
models of hepatic fibrosis, murine schistosomiasis and 
CC14-treated  rats,  were examined,  they both exhibited 
increased levels of TGF-31  gene expression at times 
that somewhat preceded the increase in collagen syn- 
thesis.  In contrast,  in murine schistosomiasis, mRNA 
levels of tumor necrosis factor and  interleukin-I 
peaked early in the fibrogenic process. Immuno- 
histochemical analysis showed TGF-31  to be present in 
normal mouse liver and to be markedly increased in 
mice infected with schistosomiasis.  TGF-31  appeared 
in the'hepatic parenchyma,  primarily in hepatocytes. 
These findings strongly suggest a  role for TGF-31  in a 
pathophysiological state. 
T 
RANSFORMING growth  factor-3  (TGF-3) * was  first 
named for its ability to induce a reversible phenotypic 
transformation  of cells in culture (27, 31, 44), but many 
other properties of this cytokine have been subsequently de- 
scribed (35, 46). 2 Many cell types including  lymphocytes, 
platelets,  and macrophages synthesize  this polypeptide (12, 
33),  and  essentially  all  cells have a  specific,  high  affinity 
TGF-3 receptor (19, 30, 48). This cytokine has been impli- 
cated as having a major role in the production of extracellular 
matrix  proteins.  TGF-3 has been shown to induce collagen 
formation  in  rodent (24),  chicken (25),  and  human  fibro- 
blasts (40)  and in rat  myoblasts (24),  and this  increase in 
collagen  synthesis  has  been shown  to  be associated with 
enhanced  steady-state  procoUagen  mRNA levels  (24,  40). 
TGF-3 is also known to stimulate the production of other ma- 
trix components such as fibronectin  and proteoglycans  (16, 
24, 25, 40). When administered  to mice, TGF-3 increases 
the  formation  of collagen  in  granulation  tissue  (41) and 
hastens  wound healing  (32). 
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1. Abbreviations  used in this paper: IL-1, interleukin-1; TGF-3, transforming 
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2. It is our assumption that most studies mentioned in this manuscript have 
actually investigated TGF-fll, however we make this distinction only in our 
own investigation. 
The extremely low concentration  at which TGF-3 exerts 
effects on hepatocytes in culture (21), and its apparent regula- 
tory function in matrix  formation,  have led us to investigate 
this cytokine for a possible role in a pathophysiological  con- 
dition,  hepatic fibrogenesis.  The cirrhotic liver is marked by 
a disordered and increased deposition of several matrix pro- 
teins.  However, the increase in collagen  content is particu- 
larly significant in the pathophysiology  of this disorder (9), 
with type I collagen  predominating  in  advanced  cirrhosis 
(42). The mechanism  of this increased  collagen synthesis is 
unknown.  Suggestions  have  been made that  cytokines re- 
leased by macrophages  or lymphocytes may be important  in 
inducing hepatic fibrosis (17, 38, 39, 51), but it has not been 
determined which factor(s) may be primarily responsible.  In 
this study, we have attempted to delineate the role of TGF-31 
in hepatic  fibrogenesis  by examining  the following:  the ef- 
fects of this protein on collagen synthesis by hepatic cells in 
vitro; the level of gene regulation  at which TGF-31 affects 
collagen gene expression;  and finally, whether TGF-31 gene 
expression and protein synthesis are stimulated in two animal 
models of hepatic fibrogenesis,  murine schistosomiasis  and 
CCh-induced hepatotoxicity  in rats. 
Materials and Methods 
Cell Culture and In Vitro TGF-31 Treatment 
Male Sprague-Dawley rats were maintained under  12-h light/dark cycles 
and allowed food and water ad libitum. Single cell suspensions of hepato- 
cytes were obtained from liver perfusions of rats weighing between 200 and 
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of Leffert et al. (28). The cells were cultured on plastic dishes in RPMI 1640 
(Gibco Laboratories, Grand Island, NY) supplemented with 100 IU/ml pen- 
icillin, 100/zg/ml streptomycin, and a mixture of hormones, growth factors, 
and trace elements to produce a hormonally defined medium as previously 
described (15).  For the first 4  h after isolation, the cells were also main- 
rained in 10% fetal bovine serum (Hyclone Laboratories, Logan, UT). Half 
of the cells were treated during the second 24 h of culture with varying con- 
centrations of TGF-B1 (Collagen Corp., Paio Alto, CA). The biological ac- 
tivity of TGF-BI  was maintained by dissolving it in a 0.01 N HCI solution 
with 1 mg/ml bovine serum albumin. Equal amounts of 0.01 N HCI and bo- 
vine serum albumin were added to control cells. Both control and treated 
cells received 50 #g/ml ascorbic acid during this second 24-h period. At 
the end of  the 24 h of treatment, the cells were harvested for RNA extraction 
or nuclear run-on assays. The cells were cultured for only 48 h in a hor- 
monally defined medium to limit hepatocyte dedifferentiation and mesen- 
chymal cell overgrowth (15), and during this period >90% of the cells were 
hepatocytes. 
Animal Models 
CFI  female mice were infected subcutaneously with 50 cercariae of the 
Puerto Rican strain ofSchistosoma mansoni (received from the Department 
of Geographic Medicine, Case Western Reserve Medical School, Cleve- 
land,  OH),  and  littermate controls were provided by the  same  source. 
Animals were killed by cervical dislocation at 5-8 wk after infection. Por- 
tions of liver were used for RNA extraction, nuclear run-on assays, or im- 
munohistochemistry. Histologic sections of liver from the dead mice were 
evaluated  by hematoxylin and eosin, and trichrome stains. 
Male Sprague-Dawley rats weighing 60-80 g were treated with CC14. 
They  received intraperitoneal  injections of increasing concentrations of 
CCI4 three times a  week for <8 wk as previously described (36).  These 
animals were killed at weekly intervals from 5 to 8 wk after the start of the 
injections. As with the schistosoma-infected mice, portions of liver were 
then used for RNA extraction or histologic examination. 
RNA Extraction and Northern Blot Hybridization 
Cultured hepatic cells (10) or animal livers (54) were used for RNA extrac- 
tions using a modification of the Chirgwin procedure (5). The cell pellets 
or liver specimens were homogenized in 3.5 ml ofa 4 M guanidine thiocya- 
nate solution, and after a low speed centrifugation to remove cellular debris, 
the RNA was pelleted through a cesium chloride gradient. After a series 
of ethanol precipitations, total RNA content was calculated by A26o spec- 
trophotometry. For examination of the presence of some of the low abun- 
dance mRNAs, poly(A  +) RNA was prepared by oligo(dT) columns (Col- 
laborative Research, Inc., Waltham, MA). 
Steady-state mRNA levels were determined by Northern blot hybridiza- 
tion using samples of 10-20 #g of total RNA or 5/~g of poly(A  +) RNA (11). 
Filters were probed with the following eDNA clones: rat c~2(I) collagen 
(20), rat albumin (55), chicken/3-actin (7), human TGF-/31 (12), human tu- 
mor necrosis factor (TNF) (53), and mouse interleukin-1  (IL-1) (29). The 
hybridized filters were washed under stringent conditions, exposed to x-ray 
film, and the developed film scanned by densitometry. 
Transcriptional Rate A nalysis 
Nuclear run-on assays were performed on the cultured cells and livers using 
methods previously described (10, 54). Control or treated cells were pooled 
from five to six 100-ram dishes per condition and cell nuclei were isolated 
as described by Jefferson et al. (26).  Liver nuclei from control and schis- 
tosoma-infected animals were isolated by eentrifugation through 2.1 M su- 
crose as described by Clayton and Darnell (6). Nuclei from either cells or 
liver were labeled for 15 min with high specific activity [32P]UTP (6), and 
the labeled RNA transcripts were isolated and hybridized with at least a ten- 
fold excess of the eDNA probes that were bound to a nitrocellulose mem- 
brane (23). Clones ofpBR322 and a mouse eDNA of arginine transfer RNA 
(provided by Dr. J.  Darnell, Jr., Rockefeller University, New York) were 
used as controls. After hybridization, the filters were washed extensively, 
digested with RNase A, exposed to x-ray film, and densitometric scanning 
was performed. 
lmmunohistochemical Staining 
Liver tissue was fixed in formalin, embedded in paraffin, and 5-/~m sections 
were cut. TGF-~I was localized in sections following a protocol similar to 
that described by Heine et al. (22), and using the avidin-biotin peroxidase 
kit from Vector Laboratories, Inc. (Burlingame, CA). After deparatiiniza- 
tion,  blocking of endogenous peroxidase, and permeabilization in hyal- 
uronidase,  the sections were blocked with  1.5%  goat serum,  1%  BSA, 
and  1%  ovalbumin for 30 min at room temperature. Sections were then 
incubated overnight at  4°C  with  an  IgG  fraction  (prepared  by  protein 
A-Sepharose chromatography) of anti-LC(I-30) at a concentration of 25 
#g/ml. This rabbit polyclonal antibody was raised to a peptide correspond- 
ing to the amino-terminal 30 amino acids of TGF-/~I. Controls included 
replacing the primary antibody with nonimmune rabbit IgG or antisera 
depleted by incubation with TGF-~i-Sepharose resin (22).  After washing 
of the sections and incubation with biotinylated goat anti-rabbit IgG and 
avidin-peroxidase as directed by the manufacturer, staining was visualized 
by incubation in 3,3'-diaminobenzidine (Sigma Chemical Co., St.  Louis, 
MO) and hydrogen peroxide. Sections were counterstained with 1% methyl 
green. 
Results 
Hepatic cells, which were predominantly hepatocytes, were 
obtained from rat liver perfusions and treated with various 
concentrations of recombinant TGF-/31 for 24 h. The cells 
were then harvested for RNA extraction, and mRNA steady- 
state levels  were analyzed by Northern blot hybridization 
using the pro t~2(I) collagen, albumin, and B-actin cDNA 
clones. The mRNA content for pro et2(I) collagen was mark- 
edly elevated in TGF-Bl-treated cells (Fig.  1).  In contrast, 
TGF-~I  treatment did  not. significantly alter  steady-state 
mRNA levels  for another secreted protein albumin, while 
mRNA levels for the constitutive protein/~-actin were only 
slightly elevated (Fig.  1).  Densitometry scanning results of 
Northern  blots  from  four  such  experiments  showed  that 
TGF-B1 treatment increased type I procollagen mRNA levels 
by over 13-fold while having no significant effect on albumin 
or/3-actin steady-state levels. 
Given this data, and the demonstration that TGF-/3 stimu- 
lates extracellular matrix synthesis in a  variety of mesen- 
chymal cells, we examined the possible role of this protein 
in an animal model of  fibrogenesis; i.e., murine schistosomi- 
asis.  Hepatic  schistosomiasis,  one of the world's leading 
causes of  chronic liver disease in man, results from the depo- 
sition of parasite eggs in the liver sinusoids where a resultant 
inflammatory response leads to granuloma formation and 
fibrosis.  This fibrotic reaction involves the excessive deposi- 
tion of new connective tissue matrix of which collagen is the 
major component (14). Previously, we have shown that this 
increase in hepatic collagen content is accompanied by ele- 
vated levels of types I and IV procollagen mRNA (54). 
CF1 mice were subcutaneously infected with S. mansoni, 
and the animals were then killed weekly from 5 (the time of 
earliest inflammation and granuloma formation) to 8 wk. 8 
wk was chosen as a final endpoint because it has been shown 
to be the time of maximal collagen synthesis in this model 
(47).  Portions of the livers were then used for histologic ex- 
amination, RNA extraction, nuclear run-on assays, and im- 
munohistochemical staining. Review of histologic sections 
taken sequentially from 5 to 8 wk after infection shows an 
increase in the size of granulomas, along with larger deposits 
of collagen.  This  increase in  fibrosis  is mirrored by the 
Northern blot analysis of pro t~2(I) collagen mRNA levels 
which begin to rise at 5 to 6 wk, and peak at 8 wk after infec- 
tion (Fig. 2). Total RNA was also hybridized with a human 
TGF-~I cDNA clone. While TGF-/~I mRNA was detected by 
Northern blots in small amounts in normal livers from litter- 
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Northern  blot hybridizations of 
total RNA from cultures of pri- 
mary hepatic cells untreated or 
treated with TGF-B1. Single cell 
suspensions of hepatic cells were 
prepared and the cells were cul- 
tured  for 24  h  in  RPMI  1640 
supplemented  with  antibiotics, 
10% fetal bovine serum, and a 
mixture  of hormones,  growth 
factors,  and  trace  elements  to 
produce  a  hormonally  defined 
medium.  The  cells  were  then 
grown  for 24 h  in hormonally 
defined medium without serum, 
but  with  50 #g/ml of ascorbic 
acid  alone,  or  in  addition  to 
varying concentrations of TGF- 
HI. Total RNA was then extract- 
ed from the cells and subjected 
to Northern  blot  hybridization 
analysis as described  in Mate- 
rials  and  Methods.  Shown are 
autoradiograms  of  total  RNA 
from untreated control cells and from cells treated with 0.1 and 0.5 
nM TGF-/~I, and then hybridized with pro a2(I) collagen (Type I 
Col), albumin,  and B-actin cDNA probes. 
mate controls,  there  was a  significant increase in  TGF-~I 
mRNA content in the fibrotic livers from the schistosoma- 
infected animals (Fig. 2). Moreover, this imrease in TGF-~I 
steady-state mRNA levels approximately paraUeled,  and some- 
what preceded, the increase in collagen synthesis and type 
I procollagen mRNA levels. Densitometry scanning of North- 
ern blots from three separate experiments revealed a greater 
than ninefold increase in TGF-/31 mRNA levels in the livers 
of the mice at 8 wk after infection with S.  mansoni as com- 
pared to controls. To determine the level of gene expression 
responsible for this change in TGF-/~I  mRNA steady-state 
content, transcriptional rate analysis was performed on por- 
tions of liver from control and 8-wk infected mice. TGF-/31 
gene transcription at 8 wk after infection was found to be in- 
creased 1  l-fold in three sets of nuclear run-on assays (Fig. 3). 
The RNA samples extracted from the livers at 5-8 wk after 
infection were evaluated  for the  expression of three other 
genes.  These samples were probed for two other cytokines 
thought to be important in inflammation and collagen synthe- 
sis: TNF and IL-I (4,  13,  18, 45). In addition, albumin gene 
expression was analyzed.  Unlike TGF-~I, the induction of 
gene expression for these two cytokines did not follow the 
pattern seen with type I collagen. Little if any TNF or IL-1 
mRNA was present on Northern blots when the total liver 
RNA  samples were probed with cDNAs  from these cyto- 
kines.  However, when poly(A  ÷) RNA was probed with the 
TNF and IL-1 cDNAs, a distinctive and comparable pattern 
emerged. Neither cytokine mRNA could be found in normal 
liver, but detectable mRNA levels appeared with the initia- 
tion of the fibrotic response at 5-6 wk,  peaked at 6-7 wk, 
and  then declined  at  8  wk  (Fig.  2).  In contrast,  albumin 
mRNA content was greatest in the normal liver and declined 
with the progression of fibrosis (Fig.  2). 
A  hepatotoxic  model  of  fibrogenesis,  chronic  CCl4-in- 
duced fibrosis in rats,  was also used to investigate the role 
of TGF-/31 in vivo. Sprague-Dawley rats were treated three 
times a  week with  intraperitoneal  injections of CC14, and 
then killed at 5-8 wk after the start of these injections  for 
histologic examination and  RNA isolation.  Again,  the  se- 
quential increase in fibrosis was reflected in a rise in pro ~2 
(I) collagen mRNA levels which peaked at week 8. When to- 
tal RNA was hybridized with the TGF-/31 cDNA clone, the 
TGF-/~I  mRNA levels rose in concert with those for type I 
collagen (Fig.  4). 
The presence of TGF-~31 in normal mouse liver, and schis- 
tosoma-infected mouse liver, was also demonstrated by means 
of immunohistochemical staining using an antibody raised to 
a peptide corresponding to the first 30 amino acids of TGF- 
/31. This antibody is believed to stain TGF-~I at sites of syn- 
thesis (Flanders, K. C., N. L. Thompson, D. S. Cissel, L. R. 
Ellingsworth,  M.  B.  Sporn, and A. B.  Roberts, manuscript 
submitted for publication). Normal mouse liver demonstrated 
light, positive staining (Fig. 5 A), which was not seen using 
normal rabbit IgG. Positive staining was also not present when 
the TGF-Bl-specific antibody was removed from the IgG frac- 
tion by incubation with a Sepharose resin coupled with TGF- 
/~1 before its use. Mouse liver 8 wk after infection with Schis- 
tosoma mansoni showed a marked increase in staining, with 
the reactivity occurring in the hepatic parenchyma, primar- 
ily in hepatocytes (Fig.  5  B). 
Discussion 
The liver is composed of a  variety of cells organized in a 
Figure 2.  Autoradiogram  of Northern blots  with RNA extracted 
from a macrophage cell line (Ma) from livers of control mice (Nor) 
or from mice infected with S. mansoni and killed after a specified 
number of weeks of infection (5-8 wk). Poly(A  +) RNA was pre- 
pared from the total RNA samples for use in hybridization studies 
for TNF and IL-I. The RNA was denatured,  electrophoresed,  and 
hybridized with pro tx 2(1) collagen (Type I Col), TGF-/31, TNF, IL- 
l,  and  albumin  cDNA  probes  as  described  in  Materials  and 
Methods. 
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clear run-on assay showing  the tran- 
scriptional  rate of TGF-fll  in the 
liver of a pair of normal CF-I mice 
(Con), and littermates 8 wk after 
infection with S. mansoni (SCH). 
The nuclei were isolated and the 
RNA transcripts labeled as previ- 
ously described. The RNA transcripts were hybridized with TGF- 
/31, plasmid pBR322, and mouse transfer RNA (T-arg). 
scaffolding of extracellular matrix. Multiple factors may be 
involved in maintaining the proper equilibrium between ma- 
trix deposition and remodeling. During chronic hepatic in- 
jury there is a shift in this homeostatic system so that there 
is a relative overabundance of the fibrogenic factors, result- 
ing in hepatic fibrosis and eventual cirrhosis. These investi- 
gations examined the specific role of TGF-/3 in hepatic sys- 
tems  because  this  cytokine has  been  shown  to  stimulate 
collagen synthesis in other in vitro and in vivo models. 
TGF-/31 increased type I procollagen mRNA levels in pri- 
mary cultures of hepatic cells >13-fold. An analysis of tran- 
scriptional rates of our cultured hepatic cells by use of the 
nuclear run-on assay showed no difference in collagen gene 
transcription with TGF-/31 treatment (data not shown). This 
finding of posttranscriptional regulation of type I collagen is 
consistent with the results of Raghow et al. (40), who did not 
find a transcriptional level of regulation when collagen syn- 
thesis  was  evaluated using  nuclear run-on assays  in TGF- 
/3-treated fibroblasts.  However, deCrombrugghe and co-work- 
ers (43) have suggested that a binding site for nuclear factor 
I mediates TGF-~ transcriptional control of the mouse a2(I) 
collagen gene. Their studies used the chloramphenicol acet- 
yltransferase transient expression assay.  Thus,  the mecha- 
nism by which TGF-/3 enhances procollagen mRNA content 
in vitro is not entirely clear, and other recent investigations 
have shown that the degree of cell confluence is a variable, 
which may explain these differing results (37). 
In two in vivo models of hepatic fibrogenesis we demon- 
strated a marked increase in TGF-/31 gene transcription and 
mRNA levels during the period of maximal collagen synthe- 
sis. The two systems are complementary since they represent 
two distinct forms of hepatic fbrosis caused by different etio- 
logical agents.  CC14 administration results in fibrosis from 
a  toxic injury to hepatocytes which  involves a  panlobular 
inflammatory response resulting in a prominent, but not ex- 
tensive, increase in collagen synthesis. In contrast, hepatic 
murine schistosomiasis is the result of an immune response 
to a foreign antigen (the schistosoma egg), and is character- 
ized histologically by multiple focal granulomas consisting 
of eosinophils, mesenchymal cells, and macrophages as well 
as a marked increase in collagen synthesis (up to 20 times 
control levels [14]).  Thus, in two very disparate models of 
hepatic  fibrosis,  TGF-~I  gene  expression  was  associated 
with the increase in collagen synthesis.  Although TGF-B1 
treatment increased procollagen mRNA  levels in cultured 
hepatic cells within 24 h, there was approximately a l-wk de- 
lay in the rise in procollagen mRNA  in relation to the in- 
crease in TGF-B1 in our in vivo models. We can only specu- 
late about the possible causes of this lag period. The delay 
may have been largely artifactual due to the fact that the livers 
were only analyzed at weekly intervals. Or it may reflect the 
increased complexity of the in vivo situation. For example, 
this lag may be due to the need in vivo to activate TGF-fll 
from its inactive to active form (52). 
Immunohistochemical analysis substantiated our findings 
at the RNA level: low levels ofimmunoreactive  TGF-fll were 
present in normal liver, and increased staining was clearly 
observed in the hepatic parenchyma in schistosoma-infected 
livers. This positive staining occurred predominantly in he- 
patocytes, and to a lesser extent in endothelial and Kupffer 
cells. Although our immunohistochemical data may partially 
represent TGF-/31 being  processed or  metabolized  in  the 
liver (8), the increased staining in the sch~stosoma-infected 
animals with an antibody believed to stain TGF-fll at sites 
of synthesis,  suggests that hepatocytes are capable of syn- 
thesizing TGF-/5'I. This finding is in contrast to that of Braun 
et al. (3), who found that in a regenerating liver after partial 
hepatectomy, TGF-/31 mRNA was present in endothelial cells 
but not hepatocytes isolated by liver perfusion. In situ hy- 
bridization could be used to further delineate the cell type(s) 
synthesizing TGF-/31 in normal and fibrotic liver. 
These findings as well as the work of others, lead to a theo- 
retical scheme for the hepatic fibrogenic process. The liv- 
er  is  injured by a  toxin (such  as  CCh  or ethanol),  or an 
immune-mediated  response  (schistosomiasis),  stimulating 
monocytes/macrophages to release a variety of  effector  mole- 
cules such as TNF, IL-1,  and TGF-/31. Our results suggest 
that TNF and  IL-1  synthesis may be enhanced during an 
early stage of fibrosis. Since TNF and IL-1 have been shown 
to enhance each other's production in vitro (34), it is not sur- 
prising to see them stimulated in unison in vivo. Release of 
these two cytokines could initiate a complex set of responses 
that enhance fibrogenesis. TNF and IL-1 are potent mitogens 
for fibroblasts and other mesenchymal cells (13, 49), as well 
as stimulators of the inflammatory response. The stimulation 
of the inflammatory response by these proteins in the face of 
continued liver damage may perpetuate the cycle of tissue in- 
jury and repair. In addition, their mitogenic effects on mes- 
Figure 4. Autoradiogram of Northern blots with RNA isolated from 
the livers of control rats (Normal) or rats treated with CCh. After 
a specific number of weeks of CC14 treatment (5-8 wk), total RNA 
was extracted and hybridized with pro a2(I) collagen (Col I) and 
TGF-fll cDNA probes. 
The Journal of Cell Biology,  Volume 108, 1989  2480 Figure 5. Immunohistochemical staining of TGF-/31 in livers from a control mouse (A), and a mouse after 8 wk of infection with schistosomi- 
asis (B). The control mouse shows very light, positive staining in hepatocytes of the centrilobular area. Hepatocytes from a similar area 
of liver from a schistosoma-infected  mouse have strong cytoplasmic staining. Bars, 25 #m. 
enchymal cells enhance the recruitment of these cells for the 
matrix  overproduction that eventually  leads to fibrosis and 
cirrhosis.  IL-1  can also  stimulate  the synthesis of TGF-/~I 
(50),  as  does  macrophage  activation  (1).  Thus,  increasing 
levels of TGF-/5'I are present in the later stages of fibrogenesis 
when the increased matrix deposition takes place. At this late 
stage in the process,  (7-8  wk in our models)  the synthesis 
of TNF and IL-1 decline and the effects of TGF-~I on matrix 
synthesis become paramount. 
These data do not of course preclude the possibility that 
other cytokines may be involved in hepatic fibrogenesis.  In 
fact, a more complex temporal sequence or cascade of sev- 
eral cytokines,  including some  not evaluated  in this study, 
may well be instrumental in the development of hepatic fibro- 
sis.  However, the combined findings that TGF-~I  markedly 
stimulates  the synthesis of extracellular  matrix  proteins in 
hepatic and mesenchymal cells, and that the gene expression 
and production of this cytokine is increased in parallel with 
collagen gene expression and synthesis in two model systems 
of fibrogenesis,  are highly suggestive that TGF-/31 may be a 
mediator of the hepatic fibrogenic reaction.  To our knowl- 
edge,  this is the first time that this regulatory molecule has 
been directly associated  with a disease  state. 
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